Лучшие больницы для «Uterine Cancer Treatment» в Хайдарабад, Индия

The total cost of uterine cancer treatment depends on the stage of disease, the chosen modality, and whether adjuvant therapy (radiation, chemotherapy, or immunotherapy) is required. In India, a minimally invasive robotic hysterectomy with sentinel lymph node biopsy for early-stage disease typically costs USD 4,000–8,000, while a comprehensive treatment package for advanced-stage disease — including open radical hysterectomy, IMRT radiation, and multiple cycles of carboplatin/paclitaxel chemotherapy — can range from USD 12,000–18,000. In the UAE, the equivalent early-stage robotic surgical package is priced at approximately USD 9,000–15,000, and advanced multimodal treatment costs USD 22,000–35,000. Both destinations offer costs that are 50–75% below equivalent treatment in the United Kingdom or the United States. Importantly, the oncologic protocols — surgical techniques (robotic, ICG sentinel node mapping), radiation technology (IMRT/VMAT, HDR brachytherapy), and drug regimens (including pembrolizumab immunotherapy for eligible patients) — are equivalent in quality at JCI-accredited partner hospitals in both countries. GAF Healthcare provides a detailed, itemized cost estimate based on your specific diagnosis and treatment plan before you commit to travel.

The minimum safe stay before international air travel depends on the treatment modality received. Patients who undergo robotic-assisted or laparoscopic hysterectomy (minimally invasive surgery) without adjuvant therapy are typically cleared for long-haul flights at 21 days (3 weeks) post-operatively, provided wound healing is confirmed and DVT risk assessment is satisfactory. Patients who undergo open radical hysterectomy require a minimum of 4–5 weeks before flying. If adjuvant vaginal brachytherapy is required (3–5 outpatient fractions over 1–2 weeks), the total stay extends to approximately 5–6 weeks from the date of surgery. Patients requiring concurrent external beam chemoradiation must typically remain for 8–10 weeks in-country to complete the treatment course before receiving fit-to-fly clearance. All patients receive a formal written Fit-to-Fly certificate from the treating oncologist, and those assessed as high DVT risk (Caprini Score ≥5, or flights >4 hours) are prescribed extended low-molecular-weight heparin injections and compression stockings for the journey. GAF Healthcare's case manager builds your itinerary around these clinical milestones to ensure no patient travels before it is medically safe to do so.

Success rates for uterine cancer treatment are highly stage- and histology-dependent. Five-year overall survival rates are as follows: FIGO Stage I (disease confined to the uterine body) — approximately 90–95% with surgical treatment alone or surgery plus vaginal brachytherapy for intermediate-risk cases; FIGO Stage II (cervical stromal involvement) — approximately 70–75% with combined surgery and adjuvant radiotherapy; FIGO Stage III (regional spread to adnexa, vagina, parametria, or lymph nodes) — approximately 40–55% with multimodal treatment including surgery, EBRT, and chemotherapy; FIGO Stage IVB (distant metastasis) — approximately 15–20% at 5 years, with treatment focused on systemic chemotherapy and immunotherapy for eligible patients. The introduction of pembrolizumab (anti-PD-1 immunotherapy) for mismatch repair-deficient (dMMR/MSI-H) tumors has significantly improved progression-free survival in advanced and recurrent disease, with KEYNOTE-868 data demonstrating a 70% reduction in the risk of disease progression or death in dMMR patients receiving first-line pembrolizumab plus chemotherapy. Molecular profiling at diagnosis (POLE, MMR, p53) is therefore now standard at all GAF Healthcare partner centres, as it directly determines both prognosis and eligibility for these high-efficacy immunotherapy regimens. The gynecologic oncology teams at GAF Healthcare's partner hospitals manage hundreds of uterine cancer cases annually, with surgical complication rates and oncologic outcomes benchmarked against international standards.